Seeking Alpha

Seeking Alpha Portfolio App for iPad

393 people get PTIE articles and Market Currents by email alert.

Get email alerts on PTIE »

PTIE

Pain Therapeutics

5/19/2013, 8:19 PM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 10, 12:52 PM Midday top 10 gainers: UNIS +58%. DRAM +57%. VRML +26%. SREV +22%. MCP +20%. UBNT +18%. RH +18%. WCRX +17%. CSIQ +16%. SQNM +16%.
Midday top 10 losers: PTIE -48%. DRRX -41%. IFMI -34%. AFFY -26%. SRT -23%. LPDX -22%. OPTR -17%. REFR -16%. PANL -16%. TRMD -15%. Comment! [On the Move]
Friday, May 10, 9:10 AM Premarket gainers: PGNX +26%. UNIS +21%. UBNT +19%. SQNM +11%. MCP +11%. XIN +7%. NBG +6%. NTE +5%. MT +5%.
Losers: PTIE -48%. IFMI -36%. AFFY -18%. SNTS -7%. OPTR -7%. DDD -6%. MDRX -6%. LFVN -5%. Comment! [On the Move]
Friday, May 10, 8:12 AM Pain Therapeutics (PTIE) craters 45.5% in premarket trading after Pfizer (PFE) says it is "considering its options" on Remoxy and may not respond to the FDA's complete response letter anytime in the next two years. PTIE sub-licensed Remoxy's commercialization rights to PFE subsidiary King Pharma (I, II). Comment! [Healthcare, On the Move]
Tuesday, April 30, 12:46 PM Midday top 10 gainers: TTHI +45%. PTIE +26%. DRRX +26%. MTOR +23%. MGAM +20%. OIS +16%. GIB +14%. HGSH +15%. ARWR +13%. TXRH +13%.
Midday top 10 losers: DCTH -44%. AVEO -26%. NUAN -18%. AOSL -18%. PBI -16%. AEIS -13%. MSTR -10%. ANV -10%. ELTK -10%. SYN -10%. Comment! [On the Move]
Tuesday, April 30, 11:41 AM Pain Therapeutics (PTIE +19%) and Durect (DRRX +25.5%) both soar on the back of positive comments out of Pfizer's (PFE) conference call about Remoxy, an oxycodone capsule the pair have been developing. PTIE sub-licensed Remoxy's commercialization rights to King Pharmaceuticals, which is a subsidiary of PFE, and the pharma-giant noted in its call that it's had a productive meeting with the FDA last month regarding the drug. (PFE Conference Call Webcast) 1 Comment [Healthcare, On the Move]
Wednesday, April 24, 9:28 AM Pain Therapeutics (PTIE): Q1 EPS of -$0.01 in-line. Revenue of $1.96M misses by $0.84M. (PR) Comment! [Earnings, Breaking News]
Wednesday, April 17, 10:56 AM Shares of Pain Therapeutics (PTIE +1.4%) benefit from the FDA's "public health priority" call on abuse-deterrent opioid analgesics. PTIE is developing Remoxy, an abuse-resistant form of oxycodone in conjunction with Pfizer (PFE). Other names moving on the news: ACUR +70% and ENDP +3.2%. Comment! [Healthcare, On the Move]
Friday, April 12, 5:53 PM After-hours top gainers, as of 5:15 p.m.: PLCM +4%. WLK +4%. IM +4%. ANV +4%. RES +4%.
After-hours top losers: USLV -4%. PTIE -3%. HOLX -3%. ARP -2%. RSH -2%. Comment! [On the Move]
Wednesday, February 6, 9:45 AM Pain Therapeutics (PTIE): Q4 loss per share of $0.04 misses by $0.02. Revenues of $2.47M (-10.2% Y/Y) misses by $0.32M. Shares -2.4%. (PR) Comment! [Earnings, Healthcare]
Thursday, January 10, 12:45 PM Midday top 10 gainers: UCBA +48%. NOK +19%. VOXX +17%. NEWL +16%. FSCI +16%. MY +15%. HAST +15%. HGG +13%. SVU +12%. PTIE +11%.
Midday top 10 Losers: MCP -21%. GIG -21%. DRWI -20%. UNXL -14%. PRXI -8%. QRM -8%. ASNA -8%. THLD -8%. SSRI -8%. PRGN -7%. 1 Comment [On the Move]
Thursday, December 13, 2012, 12:45 PM Midday top 10 gainers: ONCY +51%. TELK +23%. PRGN +21%. GBR +17%. SDBT +16%. SAM +15%. BBY +15%. CLWR +14%. ZAGG +14%. TROV +13%.
Midday top 10 Losers: RIGL -35%. EVI -31%. HRG -26%. PTIE -19%. CBMX -18%. OSN -15%. MEIP -13%. DQ -12%. CSUN -12%. ALLT -11%. Comment! [On the Move]
Thursday, November 1, 2012, 12:45 PM Midday top 10 gainers: HGSH +78%. WMCO +41%. KSWS +35%. CHC +32%. REDF +26%. GTIV +23%. WNC +22%. IMH +20%. JDAS +17%. NEWP +16%. Midday top 10 Losers: CMVT -48%. DRRX -39%. PTIE -30%. ABMD -30%. FARO -18%. AAWW -17%. FBN -16%. GBX -14%. ZUMZ -14%. EONC -14%. Comment!
Friday, August 17, 2012, 12:22 PM Pain Therapeutics (PTIE +1.3%) moves up after being initiated with a Buy at C.K. Cooper. The firm says it wants to stay ahead of an potentially positive news on Remoxy, its extended release capsules of oxycodone being developed with Pfizer (PFE -1.2%). The FDA rejected the drug in June, but Cooper believes the stock will move higher once PFE clarifies its plans for resubmission. Comment! [Healthcare, On the Move]
Monday, June 27, 2011, 3:54 PM Pain Therapeutics (PTIE -24.7%) is Nasdaq's leading loser for the second straight session, adding to Friday's 40%-plus drop after the FDA rejected a new drug application for Remoxy, its extended release capsules of oxycodone developed with Pfizer (PFE +0.4%). Durect (DRRX -8.5%), whose technology was used to develop the drug, also adds to losses. Comment! [Healthcare, On the Move]
Monday, June 27, 2011, 9:10 AM Premarket gainers: CNU +32%. LDK +6%. ACUR +6%. ZLCS +5%. SGMO +4%. ALU +3%. SINA +3%. ERIC +3%. ASML +3%.
Losers: PTIE -29%. DRRX -16%. XCO -4%. CTIC -3%. RDN -3%. Comment! [On the Move]
Friday, June 24, 2011, 11:11 AM Durect (DRRX -28%) is another casualty of the FDA's rejection of Remoxy. Its technology - designed to discourage common methods of tampering - was used to develop the drug. PTIE -37%, PFE -1.5%. Comment! [Healthcare, On the Move]